NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients

• BOREALIS Trial - CMRG 010

• NCT05272826: Phase 2: Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients

Study of Iberdomide, Bortezomib, and Dexamethasone for ND-NTE MM Patients

This study will evaluate efficacy and tolerability of iberdomide, weekly bortezomib and dexamethasone administered in combination.

Sponsor:

Canadian Myeloma Research Group

---

ClinicalTrials.gov Identifier: NCT05272826

Official Title: A Single Arm, Multicentre, Open Label Study of Iberdomide, Weekly Bortezomib and Dexamethasone for Transplant-ineligible, Newly Diagnosed Multiple Myeloma Patients: the BOREALIS Trial

First Posted: March 9, 2022

Click here for details on Clinicaltrials.gov

---

Drug: Iberdomide

Drug: Bortezomib

Drug: Dexamethasone

---